PRaVDA: Proton Radiotherapy Verification and Dosimetry Applications (original) (raw)

2015

Abstract

PRaVDA Radiotherapy is a fundamental weapon in the battle against cancer with some 40% of patients receiving it as part of their treatment. Proton therapy (PT) enables a lower integrated radiation dose to a patient receiving radiotherapy (compared to x-rays) due to the finite range of protons and so allows more accurate targeting of the dose. The underlying physics that permits this is the proton's Bragg peak, which increases the dose deposited at a tumour site, even if deep inside the body, as well as reducing the dose to neighbouring healthy tissue. However, PT is more sensitive to uncertainties in both treatment planning and delivery than conventional x-ray treatment . To overcome these limitations of these uncertainities in planning and delivering PT, the Wellcome Trust is funding the PRaVDA Consortium to develop new concepts and instrumentation to provide accurate information about the proton beam’s dose, energy and profile before and during treatment. PRaVDA is a team of l...

Nigel Allinson hasn't uploaded this paper.

Let Nigel know you want this paper to be uploaded.

Ask for this paper to be uploaded.